英國政府取消了從法國生物科技公司Valneva購買1億劑新冠疫苗的訂單,導致該公司的股價暴跌45%。這款疫苗目前已經(jīng)進入后期臨床試驗。
英國政府表示,由于Valneva違反了協(xié)議規(guī)定的義務,因此終止與該公司的合同,但Valneva “堅決”否認這種指控。這筆訂單價值高達14億歐元(約合16.5億美元),原定于在蘇格蘭生產(chǎn)疫苗,并從2022年開始交付。
Valneva的股價在巴黎早盤交易中暴跌超過40%,跌至11歐元,之后有所反彈。
Valneva與目前市場上的其他新冠疫苗的區(qū)別在于,它能夠刺激對完整的滅活新冠病毒的免疫反應,而不是僅針對刺突蛋白產(chǎn)生反應。有科學家表示這款疫苗可以針對更多變種病毒提供保護。
這種傳統(tǒng)的疫苗設計以滅活病毒樣本刺激免疫反應,這意味著Valneva的疫苗能夠作為現(xiàn)有疫苗的補充,用作加強針,正是這個有吸引力的特點使Valneva的股價在過去一年內(nèi)翻了兩番。
目前尚不確定英國政府宣布取消訂單的具體原因,但Valneva之前曾經(jīng)警告由于供應鏈問題,在歐盟(EU)和英國之間出口疫苗存在“嚴重風險”。
目前這款疫苗仍然在進行后期試驗,預計將在今年第四季度公布試驗結(jié)果。實驗室曾經(jīng)在8月底表示,根據(jù)1期和2期臨床試驗的結(jié)果,這款疫苗的有效率有望超過80%。預計這款疫苗將在明年晚些時候獲得英國的批準。
Valneva在一份聲明中表示:“公司一直在盡最大努力與英國政府合作,包括投入大量資源和精力響應英國政府對變種病毒疫苗的要求。”
早在今年4月,Valneva與歐盟委員會(European Commission)的談判同樣以失敗告終,因為歐盟高層表示,該公司達不到“某些特定的條件”。據(jù)媒體報道,Valneva優(yōu)先處理英國訂單是雙方談判失敗的原因之一。
隨后,雙方在6月底恢復談判,這表明歐盟已經(jīng)不再將此視為障礙,但Valneva并沒有獲得歐盟的購買協(xié)議。該公司一直在與歐盟各國單獨談判疫苗合同。(財富中文網(wǎng))
譯者:劉進龍
審校:汪皓
英國政府取消了從法國生物科技公司Valneva購買1億劑新冠疫苗的訂單,導致該公司的股價暴跌45%。這款疫苗目前已經(jīng)進入后期臨床試驗。
英國政府表示,由于Valneva違反了協(xié)議規(guī)定的義務,因此終止與該公司的合同,但Valneva “堅決”否認這種指控。這筆訂單價值高達14億歐元(約合16.5億美元),原定于在蘇格蘭生產(chǎn)疫苗,并從2022年開始交付。
Valneva的股價在巴黎早盤交易中暴跌超過40%,跌至11歐元,之后有所反彈。
Valneva與目前市場上的其他新冠疫苗的區(qū)別在于,它能夠刺激對完整的滅活新冠病毒的免疫反應,而不是僅針對刺突蛋白產(chǎn)生反應。有科學家表示這款疫苗可以針對更多變種病毒提供保護。
這種傳統(tǒng)的疫苗設計以滅活病毒樣本刺激免疫反應,這意味著Valneva的疫苗能夠作為現(xiàn)有疫苗的補充,用作加強針,正是這個有吸引力的特點使Valneva的股價在過去一年內(nèi)翻了兩番。
目前尚不確定英國政府宣布取消訂單的具體原因,但Valneva之前曾經(jīng)警告由于供應鏈問題,在歐盟(EU)和英國之間出口疫苗存在“嚴重風險”。
目前這款疫苗仍然在進行后期試驗,預計將在今年第四季度公布試驗結(jié)果。實驗室曾經(jīng)在8月底表示,根據(jù)1期和2期臨床試驗的結(jié)果,這款疫苗的有效率有望超過80%。預計這款疫苗將在明年晚些時候獲得英國的批準。
Valneva在一份聲明中表示:“公司一直在盡最大努力與英國政府合作,包括投入大量資源和精力響應英國政府對變種病毒疫苗的要求?!?/p>
早在今年4月,Valneva與歐盟委員會(European Commission)的談判同樣以失敗告終,因為歐盟高層表示,該公司達不到“某些特定的條件”。據(jù)媒體報道,Valneva優(yōu)先處理英國訂單是雙方談判失敗的原因之一。
隨后,雙方在6月底恢復談判,這表明歐盟已經(jīng)不再將此視為障礙,但Valneva并沒有獲得歐盟的購買協(xié)議。該公司一直在與歐盟各國單獨談判疫苗合同。(財富中文網(wǎng))
譯者:劉進龍
審校:汪皓
The U.K. government has canceled its order of 100 million doses of the late-stage COVID-19 vaccine from France-based biotech firm Valneva—leading company shares to plummet by 45%.
The U.K. government said it had terminated the contract because Valneva was in breach of its obligations under the deal—a claim Valneva “strenuously” denies. The deal was worth up to €1.4 billion ($1.65 billion) with the vaccine set to be manufactured in Scotland. Deliveries were expected to start in 2022.
Shares in Valneva fell more than 40% in early Paris trading, hitting a low of €11 before recouping some of the losses.
The Valneva vaccine differentiates itself from the vaccines currently on the market by stimulating a reaction to the inactivated whole COVID-19 virus, rather than just targeting the spike protein, a process that some scientists say should offer protection against more variants.
This old-school vaccine design of taking a killed sample of the disease and using it to stimulate an immune response means the Valneva shot could complement existing vaccines and be used as a booster shot—an attractive feature that has helped Valvena quadruple its stock price over the past year.
It is not clear what pushed the U.K. government to serve a notice of termination, but in previous warnings, Valneva warned of a “substantial risk” to exporting the vaccine between the EU and the U.K. owing to supply chain issues.
The vaccine is currently still in late-stage trials with the results expected in the fourth quarter of this year. The laboratory noted at the end of August that based on Phase I and Phase II trials, it hoped to have a vaccine that is more than 80% effective. U.K. approval is slated for late next year.
“Valneva has worked tirelessly, and to its best efforts, on the collaboration with HMG including investing significant resources and effort to respond to HMG’s requests for variant-derived vaccines,” the company said in a statement.
Back in April, talks between Valneva and the European Commission also broke down because, the EU executive said, the company failed to meet “a certain set of conditions.” Valneva’s prioritization of the U.K.’s order was reportedly a factor.
There was a subsequent resurrection of the talks in late June, suggesting the EU no longer saw this as an obstacle, but Valneva never secured an EU purchase agreement. It has been negotiating vaccine contracts on a country-by-country basis.